Related references
Note: Only part of the references are listed.CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response
Nicholas F. Kuhn et al.
CANCER CELL (2019)
NR4A transcription factors limit CAR T cell function in solid tumours
Joyce Chen et al.
NATURE (2019)
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
Eric L. Smith et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
Adam D. Cohen et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
A safe and potent anti-CD19 CAR T cell therapy
Zhitao Ying et al.
NATURE MEDICINE (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
leExploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
Jie Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection
Francesca Alfei et al.
NATURE (2019)
TOX is a critical regulator of tumour-specific T cell differentiation
Andrew C. Scott et al.
NATURE (2019)
TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion
Omar Khan et al.
NATURE (2019)
γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
Margot J. Pont et al.
BLOOD (2019)
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
Zhiling Yan et al.
LANCET HAEMATOLOGY (2019)
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma
Andrea Schmidts et al.
BLOOD ADVANCES (2019)
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma (vol 3, e120505, 2018)
Alfred L. Garfall et al.
JCI INSIGHT (2019)
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
Keishi Adachi et al.
NATURE BIOTECHNOLOGY (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects
Yuki Kagoya et al.
NATURE MEDICINE (2018)
Chimeric Antigen Receptor Therapy
Carl H. June et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy
Atsutaka Minagawa et al.
CELL STEM CELL (2018)
T Cells Expressing Anti B-Cell Maturation Antigen Chimeric Antigen Receptors for Plasma Cell Malignancies
Chunrui Li et al.
BLOOD (2018)
Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial
Sham Mailankody et al.
BLOOD (2018)
The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy
Naoki Hosen et al.
NATURE MEDICINE (2017)
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
Waseem Qasim et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes
Tea Gogishvili et al.
BLOOD (2017)
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Syed Abbas Ali et al.
BLOOD (2016)
Regeneration of CD8αβ T Cells from T-cell-Derived iPSC Imparts Potent Tumor Antigen-Specific Cytotoxicity
Takuya Maeda et al.
CANCER RESEARCH (2016)
Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells
Michael Boice et al.
CELL (2016)
Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors
Kole T. Roybal et al.
CELL (2016)
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
Avery D. Posey et al.
IMMUNITY (2016)
Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
Carlos A. Ramos et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Ionic immune suppression within the tumour microenvironment limits T cell effector function
Robert Eil et al.
NATURE (2016)
Chimeric Antigen Receptor T Cells in Myeloma
Alexander Shimabukuro-Vornhagen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chih-Hao Chang et al.
CELL (2015)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
H. M. Lokhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Tolerance and exhaustion: defining mechanisms of T cell dysfunction
Andrea Schietinger et al.
TRENDS IN IMMUNOLOGY (2014)
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Robert O. Carpenter et al.
CLINICAL CANCER RESEARCH (2013)
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients
N. Hosen et al.
LEUKEMIA (2012)
CD19-CD45low/-CD38high/CD138+ plasma cells enrich for human tumorigenic myeloma cells
D. Kim et al.
LEUKEMIA (2012)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Michael Kalos et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Sid P. Kerkar et al.
CANCER RESEARCH (2010)
Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial
Renier Brentjens et al.
MOLECULAR THERAPY (2010)
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance
William Matsui et al.
CANCER RESEARCH (2008)